The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.

The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA.sub.B receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA.sub.B receptor agonist.

The invention is associated with ingestible film coated solid dosage forms comprising natural honey in the coating applied to such forms. The natural honey of the film coated solid dosage form is of sufficient level to be perceived by the user while avoiding sticking to each other or the packaging with which they are in contact and, or storage.

The invention provides methods for treating a patient with a disorder, such as a GI disorder or symptoms associated with a GI or non-GI disorder, by administering a therapeutically effective amount of a delayed release pharmaceutical composition comprising linaclotide.

A process for producing a cellulose ether acetate succinate comprises the step of reacting a cellulose ether with acetic anhydride, succinic anhydride and an depolymerizing agent, wherein the cellulose ether has an initial viscosity of at least 50 mPa-s, measured as a 2 weight-% solution in water at 20° C., and the reaction of the cellulose ether with acetic anhydride, succinic anhydride and the depolymerizing agent is conducted simultaneously or in sequence in one reaction device.

It is an object of the present invention to provide a Janus nanoparticle, into which a drug can be encapsulated by a simple method, and a method for producing the same. According to the present invention, provided is a method for producing a Janus nanoparticle having a particle diameter of 0.01 to 5000 μm, which is composed of a lipid and a polymer, wherein the method comprises: a step of emulsifying a solution of one or more types of lipids and one or more types of polymers dissolved in a common solvent in an aqueous solution of a surfactant(s); and a step of removing the common solvent from the obtained emulsion.

Provided is a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I

##STR00001##

as a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I), wherein typically the composition is coated with an enteric coating and its use in the treatment of cancer.

The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.

A pharmaceutical or nutraceutical composition, contains a) a core a), containing a pharmaceutical or a nutraceutical active ingredient and b) a coating layer b), containing a mixture of 80 to 96% by weight of a water-insoluble (meth)acrylate polymer and 4 to 20% by weight of guar gum, wherein the water-insoluble (meth)acrylate polymer contains polymerized units of more than 95 and up to 100% by weight C.sub.1-C.sub.4-alkyl esters of acrylic acid or of methacrylic acid and less than 5% by weight of acrylic acid or methacrylic acid.

A system and method are provided for securing an ingestible electronic device to a pharmaceutical product without damaging the ingestible electronic device. The product includes the ingestible electronic device being placed on the product in accordance with one aspect of the present invention, in accordance with another aspect of the present invention, the ingestible electronic device is placed inside the product. Various embodiments are disclosed in accordance with the present invention for protecting and/or coating of the electronic marker as well as securing the ingestible electronic device onto the product.